Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation factor concentrates: past, present, and future.

Nigel S Key1, Claude Negrier

  • 1University of North Carolina School of Medicine and Harold R Roberts Comprehensive Hemophilia Diagnostic and Treatment Center, Chapel Hill, NC, USA. Nigel_Key@med.unc.edu

Lancet (London, England)
|August 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.

Research and practice in thrombosis and haemostasis·2026
Same author

Relationships between bleeding assessment tools (ISTH-BAT, Self-BAT) and quality of life in patients with bleeding symptoms.

Research and practice in thrombosis and haemostasis·2026
Same author

florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay.

Blood advances·2025
Same author

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.

The New England journal of medicine·2025
Same author

When sickle cell trait is not just trait: risk of VTE.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Clotting factor concentrates have improved significantly, reducing pathogen transmission risks for hemophilia patients. Future treatments focus on bioengineered proteins to enhance efficacy and reduce immunogenicity.

Area of Science:

  • Biotechnology
  • Hematology
  • Infectious Disease Prevention

Background:

  • Transfusions with pooled plasma in the 1970s-1980s led to widespread HIV and hepatitis C infections.
  • This crisis spurred the development of safer clotting factor concentrates.
  • Current concentrates have an excellent safety record regarding pathogen transmission.

Purpose of the Study:

  • To review the evolution of clotting factor concentrates.
  • To highlight advancements in safety and remaining therapeutic challenges.
  • To discuss future directions in recombinant protein therapies.

Main Methods:

  • Review of historical data on transfusion-related infections.
  • Analysis of technological advancements in factor concentrate production (donor screening, virucidal technologies, recombinant DNA technology).

Related Experiment Videos

  • Discussion of current and future challenges in hemophilia treatment.

    • Main Results:

    • Recombinant factor concentrates have drastically reduced the risk of blood-borne pathogen transmission.
    • Key challenges persist, including prion transmission risk, alloantibody formation, and global access disparities.
    • Bioengineered proteins offer potential for improved pharmacokinetic properties and reduced immunogenicity.

    Conclusions:

    • Significant progress has been made in the safety of clotting factor concentrates.
    • Addressing remaining challenges is crucial for comprehensive hemophilia care.
    • Future therapies will likely involve advanced bioengineered recombinant proteins.